Turning Point Therapeutics, Inc. clinical trials
Acquired by Bristol-Myers Squibb, Aug 17, 2022 · source ↗
The registry lists 9 studies whose lead sponsor is Turning Point Therapeutics, Inc.. 2 are recruiting or about to start. Per ClinicalTrials.gov, last updated Sep 25, 2026.
Before and after it joined Bristol-Myers Squibb
- First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- 7
- First submitted after Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- 2
- Unclear, or no submission date
- 0
By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.
Registry sponsor names on this page
- Turning Point Therapeutics, Inc.9 studies
Something wrong with this grouping? Tell us on the Bristol-Myers Squibb page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Bristol-Myers Squibb studies →
- A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 AlterationsRecruitingNCT04094610Phase 1/2
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in METActive, not recruitingNCT03993873Phase 1
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- A Phase 1 Study to Evaluate the Potential Drug Interactions Between Repotrectinib and Metformin, Digoxin, and Rosuvastatin in Patients With Advanced Solid TumorsWithdrawnNCT05828303Phase 1
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted after Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or MutationsTerminatedNCT04161391Phase 1/2
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- Study of Turning Point Therapeutics LM-302 in Patients With Advance Solid TumorsCompletedNCT05001516Phase 1
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- A Study of Repotrectinib in Combination With Other Anticancer Therapies for the Treatment of Subjects With KRAS-Mutant Solid TumorsTerminatedNCT05071183Phase 1/2
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer PatientsWithdrawnNCT05828277Phase 1
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted after Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb
- A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLCTerminatedNCT04849273Phase 1
Sponsor listed in the registry: Turning Point Therapeutics, Inc. · First submitted before Turning Point Therapeutics, Inc. became part of Bristol-Myers Squibb